TALECRIS VISION
CORPORATE SITES
Talecris Canada
Talecris Europe
Talecris Corporate
View All
PRODUCT SITES
Alpha-1 Antitrypsin Deficiency
(Prolastin/Prolastina)
Immune Globulin Intravenous
Therapy
(IGIV) (Gamunex)
Antihemophilic Factor VIII
(Koāte-DVI)
Antithrombin III
(Thrombate III)
Human Albumin Products
(Plasbumin / Plasmanate)
Hyperimmune Globulin Therapy
(Hypermunes)
View All
PROGRAMS & SERVICES
Gamunex Direct
Talecris Direct
Contract Manufacturing Services
Talecris Plasma Resources
View All
CONTACT TALECRIS
United States
Home
About Talecris US
Our Products
Our Services
Media Center
Careers
Media Center
Press Releases
Request Updates from Media Center
Media Center
Press Releases
To see all our press releases, visit the archive on the Talecris corporate Web site.
May 14, 2008
Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
May 08, 2008
FDA Grants Priority Review of Gamunex
®
as a Treatment for Neurological Disorder CIDP
April 28, 2008
Talecris Partners with Catalent Pharma Solutions for European Contract Manufacturing and Product Testing
March 31, 2008
Talecris Biotherapeutics Awarded Manufacturing Contract to Supply Canada with Biological Therapies for the 20th Consecutive Year
March 03, 2008
Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford
View press release archive on the Talecris corporate site.
Contact Talecris
Glossary
Site Map
General Conditions of Use
Privacy Statement
California Compliance
© 2008 Talecris Biotherapeutics